Boehringer Ingelheim and Connexios Life Sciences Enter Agreement for AMPK Activators - - BioPharm International

ADVERTISEMENT

Boehringer Ingelheim and Connexios Life Sciences Enter Agreement for AMPK Activators



Boehringer Ingelheim and Connexios Life Sciences, a Bangalore based biotechnology company, reported an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type 2 Diabetes.

As part of the agreement, Boehringer Ingelheim obtains global rights to CNX-012, Connexios Life Sciences’ program on AMPK activators. The program includes CNX-570 and other compounds in early pre-clinical development. Boehringer Ingelheim will be responsible for all further development and commercialization of the candidates from the AMPK program. Further terms and financial details were not disclosed.

Source: Boehringer Ingelheim

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines

Click here